LYL-845

N/A

Report date: 2023/11/10 13:17:01

Base Information

Drug NameLYL-845

Drug Alias NameLYL845

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesLyell Immunopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesLyell Immunopharma Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsMelanoma

Other Information

ATC CodeN/A